Onapristone - Context Therapeutics

Drug Profile

Onapristone - Context Therapeutics

Alternative Names: AR-18; IVV-1001; Onapristone - Arno Therapeutics; Onapristone extended-release; ZK 299; ZK 98299

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Context Therapeutics
  • Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Glucocorticoid receptor antagonists; Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Breast cancer; Endometrial cancer; Endometriosis; Ovarian cancer; Pregnancy; Uterine cancer

Most Recent Events

  • 16 Jan 2018 Context Therapeutics plans multiple clinical trials for Breast cancer (Metastatic disease, Monotherapy, Combination therapy) by the mid of 2019
  • 22 Dec 2017 Onapristone licensed to Context Therapeutics worldwide
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in France (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top